-
Capital, M&A & Industry Strategy2 months agoTeva Pharmaceuticals to acquire BioXcel assets for up to $125m
The agreement arises as part of BioXcel Therapeutics’ voluntary Chapter 11 proceedings in the US Bankruptcy Court for the District of Delaware, initiating a court-supervised sale...
-
Capital, M&A & Industry Strategy2 months ago
BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer
Shares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would be discontinued for futility. The...
-
Capital, M&A & Industry Strategy2 months ago
Generate Bio drops as data accidentally leaked ahead of European conference
Phase 1 data from Generate Biomedicines’ ongoing chronic obstructive pulmonary disease study demonstrated “rapid and sustained reductions” across four disease biomarkers.
-
Capital, M&A & Industry Strategy2 months ago
Biotech IPOs approach ‘escape velocity’ barring yellow flags that could threaten rebound
Twenty-five biotechs have used the IPO route to go public this year—with five of those debuts occurring this month alone. It’s the most IPOs since 2021,...
-
Capital, M&A & Industry Strategy2 months ago
DC judge rejects Merck’s IRA case more than three years after it was filed
After lengthy consideration, a DC federal judge on Monday rejected Merck’s challenge to Medicare drug price negotiations. Judge Colleen Kollar-Kotelly of the US District Court for...
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
